https://www.selleckchem.com/pr....oducts/GDC-0980-RG74
BACKGROUND Current guidelines recommend direct-acting oral anticoagulants (DOACs) over warfarin in patients with atrial fibrillation (AF) and valvular heart disease (VHD) without a mechanical valve or moderate to severe mitral stenosis. However, real-world data to support the safety and efficacy of DOACs in this patient population are lacking. OBJECTIVE Our objective was to assess the safety and effectiveness of DOACs in patients with AF and VHD. METHODS This retrospective chart review evaluated patients aged ≥ 18 years with a d
Gefällt mir
Kommentar
Teilen
